HK Stock Market Move | XTEP INT'L (01368) falls over 3% as main brand retail sales in Q3 decline by a mid-single-digit percentage year-on-year.
XTEP INT'L (01368) fell over 3%. As of press time, it was down 3.54% at HK$3.54, with a turnover of HK$12.174 million.
XTEP INT'L (01368) fell over 3%, down 3.54% as of press time to HK$3.54, with turnover of HK$12.174 million.
On the news front, on October 23, XTEP INT'L disclosed its operating conditions for the third quarter of 2026. Retail sales across all channels of the Xtep main brand fell by a mid-single-digit percentage year-on-year, with retail discounts at 7.0-7.5 off, and the channel inventory-to-sales ratio at 4.5-5 months; retail sales across all channels of the Saucony brand rose by a mid-single-digit percentage year-on-year.
A Goldman Sachs research report noted that the core brand's third-quarter retail sales were broadly in line with its expectation of a roughly 6% year-on-year decline in the second half, but Saucony was slightly below the bank's previous forecast of about a 9% year-on-year increase in the second half. CMSC International issued a research report stating that it lowered XTEP INT'L's target price by 14%, from HK$4.3 to HK$3.7, and downgraded its rating from "Overweight" to "Neutral."
Related Articles
.png)
Windward Bio (WWB.US) seeks to raise up to US$100 million in a US IPO; multiple drugs licensed from Chinese pharmaceutical companies

CICC: Cuts Hisense Home Appliances Group (00921) target price to HK$21.5; third-quarter results below expectations

HK Stock Market Move | METIS TECHBIO-P (07666) rises nearly 8%, partnering with Lilly to advance AI-driven extrahepatic LNP delivery platform collaboration; the company is expected to capture more industry incremental opportunities.
Windward Bio (WWB.US) seeks to raise up to US$100 million in a US IPO; multiple drugs licensed from Chinese pharmaceutical companies
.png)
CICC: Cuts Hisense Home Appliances Group (00921) target price to HK$21.5; third-quarter results below expectations

HK Stock Market Move | METIS TECHBIO-P (07666) rises nearly 8%, partnering with Lilly to advance AI-driven extrahepatic LNP delivery platform collaboration; the company is expected to capture more industry incremental opportunities.






